Search results
LEM Holding (VTX:LEHN) May Have Issues Allocating Its Capital
Simply Wall St. via Yahoo Finance· 2 years agoFinding a business that has the potential to grow substantially is not easy, but it is possible if...
Is LEM Holding SA's (VTX:LEHN) Latest Stock Performance A Reflection Of Its Financial Health?
Simply Wall St. via Yahoo Finance· 7 months agoLEM Holding's (VTX:LEHN) stock is up by a considerable 11% over the past week. Given the company's...
Investing in LEM Holding (VTX:LEHN) five years ago would have delivered you a 45% gain
Simply Wall St. via Yahoo Finance· 3 months agoLEM Holding SA (VTX:LEHN) shareholders might be concerned after seeing the share price drop 22% in...
Estimating The Intrinsic Value Of LEM Holding SA (VTX:LEHN)
Simply Wall St. via Yahoo Finance· 4 months agoKey Insights LEM Holding's estimated fair value is CHF1,826 based on 2 Stage Free Cash Flow to...
LEM Holding (VTX:LEHN) shareholders have earned a 15% CAGR over the last five years
Simply Wall St. via Yahoo Finance· 8 months agoStock pickers are generally looking for stocks that will outperform the broader market. And while...
Investors in LEM Holding (VTX:LEHN) have made a respectable return of 59% over the past three years
Simply Wall St. via Yahoo Finance· 2 years agoBy buying an index fund, investors can approximate the average market return. But if you buy good...
Should You Be Adding LEM Holding (VTX:LEHN) To Your Watchlist Today?
Simply Wall St. via Yahoo Finance· 5 months agoFor beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a...
Ares Capital Corporation (NASDAQ:ARCC) Q4 2023 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 4 months agoAres Capital Corporation (NASDAQ:ARCC) Q4 2023 Earnings Call Transcript February 7, 2024 Ares...
Ares Capital Corp (ARCC) Q1 2024 Earnings: Surpasses Analyst EPS Forecasts with Strong ...
GuruFocus.com via Yahoo Finance· 2 months agoGAAP Net Income: Reported at $449 million for Q1 2024, significantly exceeding the estimated $346.08...
Catalyst Pharmaceuticals: An Attractive Biopharma Bet
GuruFocus.com via Yahoo Finance· 5 months agoCatalyst Pharmaceuticals Inc. (NASDAQ:CPRX) is an attractive biopharma stock to own, given the niche...